


Fact Sheet CSL Behring


2015/16

CSL Behring Sales \$5.2 Billion



By Region

- 45.8% North America
- 29.1% Europe
- 16.6% Asia-Pacific
- 8.5% Intercontinental



By Therapeutic Area

- 46.8% Immunology
- 19.0% Hematology
- 34.2% Specialty Care

Therapeutic Focus

Major Product Approvals

CSL Behring has received a total of 29 regulatory approvals for new products or indications since 2004.

CSL Behring, a member of the CSL Group of companies, is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies to treat people with life-threatening medical conditions.

We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research.

Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia.

For more information visit www.cslbehring.com, and follow us on [@CSLBehring](https://twitter.com/CSLBehring), Bio Blog <http://blog.cslbehring.com>, cslbehring.com/ and www.linkedin.com/company/csl-behring.

Employees: 14,000+ employees worldwide

Operational Headquarters: King of Prussia, Pennsylvania, USA

Plasma Collection: CSL Plasma is one of the world's largest plasma collection organizations. The company operates more than 150 collection centers in the United States and Europe. Headquarters are in Boca Raton, Florida. Testing laboratories are located in the United States and Germany.

Manufacturing: Bern, Switzerland; Marburg, Germany; Broadmeadows, Australia; and Kankakee, Illinois, USA

R&D: CSL integrated R&D includes facilities in Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Kankakee, Illinois, USA; Tokyo, Japan; Broadmeadows and Parkville, Australia

THERAPEUTIC AREA

Immunology:

Immunological disorders, such as primary immune deficiency, idiopathic thrombocytopenic purpura, Guillain-Barré syndrome and hemolytic disease of the newborn and to prevent cytomegalovirus infection in patients following solid organ transplant

Hematology:

Coagulation or bleeding disorders, including hemophilia and von Willebrand disease

Specialty:

Alpha1-antitrypsin deficiency (hereditary emphysema), hereditary angioedema, and during surgery and for wound healing, shock, burns and sepsis

TREATMENT

Media Inquiries

Natalie deVane

Corporate Media Inquiries
+1-610-878-4468
Natalie.deVane@cslbehring.com

Chris Florentz

Corporate Media Inquiries
+1-610-878-4316
Christopher.Florentz@cslbehring.com

Jennifer Purdue

(Products: Immunoglobulins, Specialty Products)
+1-610-878-4802
Jennifer.Purdue@cslbehring.com

Greg Healy

(Products: Hemophilia, Coagulants)
+1-610-878-4841
Greg.Healy@cslbehring.com

Bernard Ronchi

CSL Ltd. Investor Relations
+613-9389-3470
Bernard.Ronchi@csl.com.au